Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Options Price in $280 Billion Earnings Swing 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Add as a preferred source on Google
REDWOOD CITY, Calif., April 24, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018. Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing first quarter 2018 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: Thursday, May 10, 2018 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 2767588
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
